Helus Pharma Announces CEO Transition and Reappoints Eric So as Interim CEO

On April 20, 2026, Helus Pharma (formerly Cybin Inc.) announced that Michael Cola has stepped down as Chief Executive Officer, effective immediately, at the request of the Board of Directors. In his place, co-founder and Executive Chairman Eric So has been appointed to resume his previous role as Interim Chief Executive Officer while the Board initiates a search for a permanent successor. Mr. So, a 20-year veteran in corporate strategy and finance, aims to ensure leadership continuity as the company advances its clinical pipeline of novel serotonergic agonists (NSAs). The company remains focused on its lead programs, HLP003 and HLP004. HLP003 is currently in Phase 3 development for major depressive disorder and has received FDA Breakthrough Therapy Designation. Helus Pharma confirmed that it expects a topline data readout from the Phase 3 APPROACH trial of HLP003 in the fourth quarter of 2026. The company also continues to progress HLP004, which is in Phase 2 development for generalized anxiety disorder.